Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAP8MV)

• Drug Name: Iron Drug Info
• Synonyms: Eisen; Feronate; Ferretts; Ferrousal; Ferrum; Hemocyte; Hierro; LOHA; PZhO; Remko; Siderol; Yieronia; Ancor B; Armco iron; Carbonyl iron; Ferrous iron; Ferrovac E; Hoeganaes EH; Iron monocation; Iron standard for AAS; ATW 230; ATW 432; Atomel 28; Atomel 300M200; Atomel 500M; Atomel 95; Atomiron 44MR; Atomiron 5M; Atomiron AFP 25; Atomiron AFP 5; DSP 1000; DSP 128B; DSP 135; DSP 135C; DSP 138; EF 1000; EF 250; EFV 250; GS 6; HS 4849; Hoeganaes ATW 230; NC 100; PZh1M1; PZh2M; PZh2M1; PZh2M2; PZh3; PZh3M; PZh4M; Ancoren 80/150; Copy Powder CS 105-175; Diseases, iron overload; EFV 200/300; EFV 250/400; F 60 (metal); FT 3 (element); Fe-40; Fe1+; Ferro-Caps; Ferro-Time; HF 2 (element); HL (iron); HQ (metal); HS (iron); Iron (Fe); Iron(III) nitrate solution; Iron, elemental; PZh-1M3; PZh-2; SUY-B 2; Vitedyn-Slo; Diseases (animal), iron overload; Ed-In-Sol; Iron (Fe1+); Iron ion (Fe+); Iron ion(1+); Iron(1+); Iron(1+) ion; Iron, ion (Fe1+); Iron, ion (Fe1+) (8CI,9CI); 3ZhP

Indication

Disease Entry	ICD 11	Status	REF
Anemia of prematurity		Approved	[1]
Folate-deficiency anemia	3A02.Y	Approved	[1]
Iron-deficiency anemia	3A00	Approved	[2]

• Therapeutic Class: Iron Supplement
• Cross-matching ID:
  PubChem CID: 23925
  ChEBI ID: CHEBI:18248
  CAS Number: CAS 7439-89-6
  TTD Drug ID: DMAP8MV
  VARIDT Drug ID: DR00317
  INTEDE Drug ID: DR0882

Molecule-Related Drug Atlas

Drug(s) Targeting Hemoglobin (HB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voxelotor	DMCS6M5	Sickle-cell disorder	3A51	Approved	[7]
Iron Dextran	DM5OY70	Iron-deficiency anemia	3A00	Approved	[3]
PolyHeme	DMV8EXG	Blood forming organ disorder	JB64.1	Phase 3	[8]
Efaproxyn	DMX7BM4	Lung cancer	2C25.0	Phase 3	[9]
Hemoglobin raffimer	DMMTL7V	Anemia	3A00-3A9Z	Phase 2/3	[10]
GBT021601	DMD3C21	Sickle-cell disorder	3A51	Phase 2/3	[11]
FBS-0701	DMR3952	Iron overload disease	5C64.10	Phase 2	[12]
HQK-1001	DM7QUN0	Beta thalassemia	3A50.2	Phase 2	[13]
5-hydroxymethyl-2-furfural	DMPFVJB	Anemia	3A00-3A9Z	Phase 2	[14]
OXY-111A	DMTH75R	Cardiovascular disease	BA00-BE2Z	Phase 1/2	[15]

Drug(s) Transported By Natural resistance-associated macrophage protein 2 (SLC11A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Manganese	DMKT129	N. A.	N. A.	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Activator	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium/bile acid cotransporter 7 (SLC10A7)	DTG1RJO	NTCP7_HUMAN	Substrate	[4]
Natural resistance-associated macrophage protein 2 (SLC11A2)	DTVKMHD	NRAM2_HUMAN	Substrate	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Friedreich ataxia protein (FXN) Main DME	DEXVHDB	FRDA_HUMAN	Substrate	[6]

References

• [1] Iron FDA Label
• [2] Drug information of Iron, 2008. eduDrugs.
• [3] Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
• [4] Modulation of macrophage iron transport by Nramp1 (Slc11a1). Immunobiology. 2007;212(9-10):751-7.
• [5] Transmembrane topology of the mammalian Slc11a2 iron transporter. Biochemistry. 2009 Sep 8;48(35):8422-34.
• [6] Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006 Sep;13(3):166-75.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
• [9] Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
• [10] Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
• [11] GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
• [12] A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
• [13] A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
• [14] 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
• [15] Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.